Philippa Burns Email

Director Research & Development . Cambridge Epigenetix

Cambridge, MA

Location

LinkedIn

Current Roles

Employees:
113
Revenue:
$17.5M
About
Cambridge Epigenetix aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification. We utilise innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com or email info@cambridge-epigenetix.com.
Cambridge Epigenetix Address
The Trinity Building, Chesterford Research Pa
Cambridge, MA
UK
Cambridge Epigenetix Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.